Publication | Closed Access
RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079)
28
Citations
0
References
2019
Year
Clinical ImmunologyHealthy SubjectsIntravenous AdministrationImmunologyPharmacotherapyImmunotherapyPharmacodynamic ModelingTranslational MedicineAutoantibodiesAntibody EngineeringIs Well ToleratedTherapeutic Drug MonitoringAutoimmune DiseaseAllergyAutoimmunityImmunologic DiseaseAntibody ScreeningPharmacologyImmunoglobulin ERepeat DosesMedicinePharmacokinetics
To characterize safety, pharmacokinetics, and pharmacodynamics of single and repeat doses of RVT-1401 administered via subcutaneous (SC) injection and intravenous (IV) infusion to healthy subjects.